← Leaderboards
Marc S Penn
Cleveland Clinic Lerner Col/Med-Cwru
$4,305,724
Attributed
$6,345,302
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–22$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$6,345,302 · 4
By mechanism
R44$3,969,157 · 2
R01$1,844,048 · 1
P01$532,097 · 1
Top collaborators
- Lawrence Mahan3 shared
- Anthony Ting3 shared
- Warren Sherman1 shared
Others in their field
Top investigators on “Lead”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$423,098,075
- David Heimbrook · Leidos Biomedical Research, Inc.$406,926,511
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$382,410,253
Research focus
LeadNovel TherapeuticsDiagnosisAcuteCardiacMorbidity - Disease RateMyocardial InfarctionInfarctionDistalInjuryDesignClinical TrialsHeartHeart FunctionCongestive Heart FailureIn VitroCardiovascular SystemCaringBaseCell TypeCessation Of LifeChemistryAcute Myocardial InfarctionCells
Grant awards (16)
A Phase 2a Clinical Study of a Cardiac Hormone for the Outpatient Treatment of Worsening Heart Failure$1
R44 · FY2022 · HL
A Phase 2a Clinical Study of a Cardiac Hormone for the Outpatient Treatment of Worsening Heart Failure$1,044,010
R44 · FY2021 · HL
A Phase 2a Clinical Study of a Cardiac Hormone for the Outpatient Treatment of Worsening Heart Failure$887,140
R44 · FY2020 · HL
Phase II Trial Evaluating the Safety and Efficacy of an Allogeneic Stem Cell for$842,506
R44 · FY2016 · HL
Phase II Trial Evaluating the Safety and Efficacy of an Allogeneic Stem Cell for$865,500
R44 · FY2015 · HL
Phase II Trial Evaluating the Safety and Efficacy of an Allogeneic Stem Cell for$330,000
R44 · FY2013 · HL
Myocardial regeneration in ischemic cardiomyopathy$362,679
R01 · FY2009 · HL · contact PI
Myocardial regeneration in ischemic cardiomyopathy$362,679
R01 · FY2008 · HL · contact PI
CORE---Animal Model$112,316
P01 · FY2008 · HL · contact PI
Myocardial regeneration in ischemic cardiomyopathy$362,679
R01 · FY2007 · HL · contact PI
CORE---Animal Model$111,340
P01 · FY2007 · HL · contact PI
Myocardial regeneration in ischemic cardiomyopathy$373,511
R01 · FY2006 · HL · contact PI
CORE---Animal Model$105,867
P01 · FY2006 · HL · contact PI
Myocardial regeneration in ischemic cardiomyopathy$382,500
R01 · FY2005 · HL
CORE---Animal Model$102,784
P01 · FY2005 · HL
CORE---Animal Model$99,790
P01 · FY2004 · HL